Loading...
Loading...
Browse all stories on DeepNewz
VisitNature Study: Inhibiting IL-11 Protein Extends Lifespan of Mice by 25%, Clinical Trials Underway
Jul 17, 2024, 04:51 PM
A recent study published in Nature reveals that inhibiting the pro-inflammatory protein interleukin-11 (IL-11) can extend the lifespan of mice by up to 25%. The research demonstrated that both genetic deletion and pharmacological inhibition of IL-11 significantly increased the median lifespan of male mice by 22.5% and female mice by 25%. The treated mice, referred to as 'supermodel grannies' due to their youthful appearance, also exhibited improved health, strength, and reduced age-related health problems. Preclinical studies support the evaluation of IL-11 inhibition on aging pathologies in older people. Anti-IL-11 therapies are already in early clinical trials for human applications, raising hopes that similar anti-aging effects could be achieved in humans. Additionally, the treatment has been shown to reduce the incidence of cancer.
View original story
Markets
No • 50%
Yes • 50%
Clinical trial registries and announcements from research institutions or pharmaceutical companies
Yes • 50%
No • 50%
Clinical trial registries and announcements from research institutions or pharmaceutical companies
No • 50%
Yes • 50%
Peer-reviewed journals and announcements from research institutions or pharmaceutical companies
Not completed • 25%
Unknown/Other • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Clinical trial registries and announcements from research institutions or pharmaceutical companies
Initiated before January 1, 2025 • 25%
Not initiated by June 30, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Clinical trial registries and announcements from research institutions or pharmaceutical companies
Not approved by any major regulatory body • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Announcements from regulatory bodies such as the FDA, EMA, or other relevant authorities